false 0001637715 0001637715 2024-09-09 2024-09-09

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 9, 2024

 

 

Reneo Pharmaceuticals, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Delaware   001-40315   47-2309515
(State or Other Jurisdiction
of Incorporation)		  

(Commission

File Number)

   (IRS Employer
Identification No.)

 

18575 Jamboree Road, Suite 275-S    
Irvine, California     92612
(Address of Principal Executive Offices)     (Zip Code)

Registrant’s Telephone Number, Including Area Code: 858 283-0280

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange

on which registered

Common stock, par value $0.0001 per share   RPHM   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b)

In connection with the contemplated merger transaction between Reneo Pharmaceuticals, Inc. (the “Company”) and OnKure, Inc. and the cessation of the Company’s historical drug development efforts, the Company terminated the employment of Ashley F. Hall, J.D., the Company’s Chief Development Officer, effective as of September 13, 2024. In connection with Ms. Hall’s termination, she will be entitled to receive the severance benefits under the Company’s severance benefit plan previously disclosed under the heading “Potential Payments Upon Termination or Change of Control” in Item 11 of the Company’s Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission on April 26, 2024.

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

      Reneo Pharmaceuticals, Inc.
Date: September 13, 2024     By:  

/s/ Gregory J. Flesher

     

Gregory J. Flesher

President and Chief Executive Officer

(Principal Executive Officer)

v3.24.2.u1
Document and Entity Information
Sep. 09, 2024
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001637715
Document Type 8-K
Document Period End Date Sep. 09, 2024
Entity Registrant Name Reneo Pharmaceuticals, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-40315
Entity Tax Identification Number 47-2309515
Entity Address, Address Line One 18575 Jamboree Road
Entity Address, Address Line Two Suite 275-S
Entity Address, City or Town Irvine
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92612
City Area Code 858
Local Phone Number 283-0280
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common stock, par value $0.0001 per share
Trading Symbol RPHM
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
Reneo Pharmaceuticals (NASDAQ:RPHM)
Historical Stock Chart
From Sep 2024 to Oct 2024 Click Here for more Reneo Pharmaceuticals Charts.
Reneo Pharmaceuticals (NASDAQ:RPHM)
Historical Stock Chart
From Oct 2023 to Oct 2024 Click Here for more Reneo Pharmaceuticals Charts.